Entrada Therapeutics (TRDA) Net Margin (2023 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Net Margin of 4539.09% for Q1 2026, down 445470.0% year-over-year from N/an in Q1 2025, and down 50.52% quarter-over-quarter from 3015.55% in Q4 2025.
Entrada Therapeutics (TRDA) Net Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' Net Margin history runs 4 years deep, the most recent figure standing at 4539.09% for Q1 2026.
- In Q1 2026, Net Margin fell 445470.0% year-over-year to 4539.09%; the TTM figure through Mar 2026 stood at 2895.57% (down 290994.0% YoY), while the FY2025 annual figure was 565.38%, down 59652.0% from the prior year.
- Net Margin for Q1 2026 stood at 4539.09%, down from 3015.55% in the prior quarter.
- The five-year high for Net Margin was 81.09% in Q3 2023, with the low at 4539.09% in Q1 2026.
- The 4-year median for Net Margin is 71.7% (2024), against an average of 974.36%.
- The sharpest annual moves came in 2024 and 2026: Net Margin surged 20077 bps in 2024, then plunged 445470 bps in 2026.
- Entrada Therapeutics' Net Margin stood at 22.71% in 2023, then soared by 113 bps to 3.02% in 2024, then sank by 99813 bps to 3015.55% in 2025, then sank by 51 bps to 4539.09% in 2026.
- Business Quant data shows TRDA's Net Margin at 4539.09% in Q1 2026, 3015.55% in Q4 2025, and 2734.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | -4,762.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,762.03% |
| Mar 31, 2026 | -4,539.09% |
| Dec 31, 2025 | -3,015.55% |
| Sep 30, 2025 | -2,734.45% |
| Jun 30, 2025 | -2,211.54% |
| Mar 31, 2025 | -84.39% |
| Dec 31, 2024 | 3.02% |
| Sep 30, 2024 | -71.70% |
| Jun 30, 2024 | 58.07% |
| Mar 31, 2024 | 39.74% |
| Dec 31, 2023 | -22.71% |
| Sep 30, 2023 | 81.09% |
| Jun 30, 2023 | -142.70% |
| Mar 31, 2023 | -26.42% |